The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-kickback statute, and create new safe harbors to protect price reductions at the point-of-sale and certain fees paid by drug makers for PBM services. In comments submitted in April to the Department of Health and Human Services’ Office of Inspector General, AHA said the rule would likely increase premiums for Medicare beneficiaries without addressing the nation’s high and rising drug prices, and urged the agency instead to consider alternative, market-based solutions aimed directly at lowering drug prices. The Campaign for Sustainable Rx Pricing, of which AHA is a founding member, said the rule’s withdrawal will allow the administration and Congress to put greater focus on such solutions.
 

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
A federal judge yesterday struck down a Centers for Medicare…
Headline
Drug makers this week increased list prices for at least 104 different drugs, dosages or package sizes, with the average price increase 13.1%, according to an…
Headline
The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.
Headline
The Senate Committee on Health, Education, Labor and Pensions today voted 20-3 to pass the Lower Health Care Costs Act (S.1895) – bipartisan legislation…
Headline
The AHA today submitted comments on the revised version of the Lower Health Care Costs Act (S. 1895), legislation to prevent surprise medical bills, reduce…